Skip to content
lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
MaxCyte, Inc
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
October 14, 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
September 23, 2026
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 20, 2026
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
May 6, 2026